Acepodia's Dr. Sony Hsiao, CEO, and Dr. Mark Gilbert, SVP of R&D, join Business of Biotech for a discussion on the company's approach to dramatically reducing the cost of cell therapy development, manufacturing, and administration via its oNK, CAR, and ACC candidates.
|